Gain Therapeutics (NASDAQ:GANX) Announces Quarterly Earnings Results

by · The Cerbat Gem

Gain Therapeutics (NASDAQ:GANX – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13), RTT News reports. During the same period in the previous year, the company posted ($0.16) earnings per share.

Gain Therapeutics Trading Down 0.3%

Shares of GANX stock traded down $0.01 during trading hours on Monday, hitting $1.82. 349,828 shares of the company were exchanged, compared to its average volume of 756,620. The firm has a market cap of $77.41 million, a PE ratio of -2.98 and a beta of 0.15. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $4.34. The company has a quick ratio of 6.63, a current ratio of 6.63 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average of $2.14 and a 200 day moving average of $2.39.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in GANX. Geode Capital Management LLC increased its stake in Gain Therapeutics by 2.9% during the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock worth $523,000 after acquiring an additional 8,251 shares during the last quarter. Marshall Wace LLP increased its stake in Gain Therapeutics by 41.0% during the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock worth $498,000 after acquiring an additional 80,407 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Gain Therapeutics during the third quarter worth about $47,000. Squarepoint Ops LLC acquired a new stake in Gain Therapeutics during the third quarter worth about $68,000. Finally, Virtu Financial LLC increased its stake in Gain Therapeutics by 126.9% during the third quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock worth $96,000 after acquiring an additional 30,207 shares during the last quarter. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gain Therapeutics in a research report on Friday, April 10th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Get Our Latest Analysis on GANX

About Gain Therapeutics

(Get Free Report)

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

Recommended Stories